Valeant Pharmaceuticals Interna (NYSE:VRX):
Valeant Announces Third Quarter Financial Results Date And Conference Call Details.
In the market the company is trading down by -7.88 percent from yesterday’s close.
It is trading at $20.35 which is just under $24.46, the 50 day moving average and a bit lower than the 200 day moving average of $26.26. The 50 day moving average was down $-4.11 or -16.81% and the 200 day average went down $-5.91 or -22.49%.
In the last earnings report the EPS was $-2.93 and is expected to be $6.49 for the current year with 347,535,000 shares outstanding. Next quarter’s EPS is estimated at $2.04 and the next full year EPS is anticipated to be $7.68.
A few Wall Street investment firms have released opinions on Valeant Pharmaceuticals Interna. Deutsche Bank started covering VRX with an initial rating of “Hold”. Morgan Stanley upgraded the stock and raised the price target on August 17 boosting the price target from $39.00 to $42.00 and altering the rating from “Equal-weight” to “Overweight”.
On August 17 the company was upgraded to “Overweight” from “Equal-weight” and a price target of $42.00 was set in a report issued by Morgan Stanley. On August 15 the stock rating was upgraded from “Underperform” to “Neutral” by Mizuho Securities.
Equity analyst BMO Capital issued its first research report on the stock by announcing an initial rating of “Market Perform”. Equity analyst JP Morgan both downgraded the stock and lowered the price target on June 23 changing the price objective from $70.00 to $40.00 and cutting the rating from “Overweight” to “Buy”.